Fertility LifeLines(TM) Offers Single Destination for Access to Infertility Information, Support and Savings

Aug 10, 2005 08:30 ET

New support services created to help consumers and patients take charge of their fertility

ROCKLAND, Mass., Aug. 10 /PRNewswire/ -- Fertility LifeLines, a free and confidential educational service from Serono, Inc., has enhanced its services to provide added value and support to the estimated six million Americans who suffer from infertility, many of whom never seek treatment. Fertility LifeLines is available at 1-866-LETS-TRY (1-866-538-7879).

Callers to Fertility LifeLines can now receive special benefits and access to potential savings on all Serono fertility products. The new benefits include a customized information kit with suggested questions to ask a doctor and a free subscription to Conceive, the leading lifestyle magazine written specifically for women trying to get pregnant. Fertility LifeLines callers can also access pharmacy services from Freedom Drug(TM), the nation's largest fertility pharmacy, including pharmacists available 24/7 and free priority overnight shipping on all orders.

"Many of our readers have questions and concerns regarding their fertility, especially ways to pay for potential treatments," says Kim Hahn, Founder and Publishing Director of Conceive and former IVF patient. "A phone call to Fertility LifeLines provides access to information and support that give people options for moving forward and taking the next step in their journey to conceive."

Fertility LifeLines provides callers with information on infertility, a summary of their infertility insurance coverage, emotional support through compassionate listening and support for Serono fertility products including one-on-one injection training over the phone and online. It is staffed with fertility nurses, insurance specialists and patient advocates who are specially trained to respond to the needs of individual callers.

"People who experience infertility often feel alone and overwhelmed, and it's important for them to have resources like Fertility LifeLines that they can turn to," says Dr. Kaylen Silverberg, Medical Director at Texas Fertility Center. "Fertility LifeLines provides a level of personal service that can benefit patients as they work with their healthcare providers to manage the many concerns they face with infertility."

Fertility LifeLines is available Monday through Friday from 8 am to midnight ET and Saturday and Sunday from 8 am to 6 pm with 24-hour access to fertility nurses and Freedom Drug pharmacists seven days a week. For more information, call toll-free 1-866-LETS-TRY (1-866-538-7879) or visit http://www.fertilitylifelines.com/.

About Infertility

Infertility is defined as the inability to achieve pregnancy after one year of regular, unprotected intercourse (six months if the woman is over 35). It affects about 6.1 million Americans, which represents about 10 percent of couples in their childbearing years. The majority of patients who complete treatment succeed in having a child.

About Fertility LifeLines

Fertility LifeLines is a free and confidential educational service provided by Serono, Inc., the leader in fertility health. Available toll-free at 1-866-LETS-TRY (1-866-538-7879), it offers a single destination for 24/7 information and support to people with concerns about infertility, including access to special benefits and potential savings on all Serono fertility products. Staffed with fertility nurses, insurance specialists and patient advocates, Fertility LifeLines is available Monday to Friday from 8 am to midnight ET and Saturday and Sunday from 8 am to 6 pm with 24-hour access to fertility nurses and Freedom Drug pharmacists. Fertility LifeLines is not meant to substitute for the advice provided by a medical professional. Callers should always consult a healthcare provider if they have health concerns. For more information about Fertility LifeLines, call toll-free 1- 866-LETS-TRY (1-866-538-7879) or visit http://www.fertilitylifelines.com/.

About Serono, Inc. and Fertility

Serono, Inc., a subsidiary of Serono S.A., is a leader in fertility health, dedicated to developing patient-friendly, innovative products that help people build families. It is the only company to offer a full portfolio of fertility medications for every stage of the reproductive cycle and recombinant versions of three hormones used in the treatment of infertility, including the Gonal-f(R) RFF Pen (follitropin alfa injection).

About Serono S.A.

Serono is a global biotechnology leader. The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R) Prefilled Syringe/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R). In addition to being the worldwide leader in reproductive health, Serono has strong market positions in neurology, metabolism and growth and has recently entered the psoriasis area. The Company's research programs are focused on growing these businesses and on establishing new therapeutic areas, including oncology. Currently, there are approximately 25 ongoing development projects.

In 2004, Serono achieved worldwide revenues of US$2,458.1 million, and a net income of US$494.2 million, making it the third largest biotech company in the world. Its products are sold in over 90 countries. Bearer shares of Serono S.A., the holding company, are traded on the virt-x (SEO) and its American Depositary Shares are traded on the New York Stock Exchange (SRA).

Package inserts for Serono's US marketed products are available at http://www.seronousa.com/ or by calling 1-888-275-7376.

Some of the statements in this press release are forward looking. Such statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Serono S.A. and affiliates to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements are based on Serono's current expectations and assumptions, which may be affected by a number of factors, including those discussed in this press release and more fully described in Serono's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 16, 2005. These factors include any failure or delay in Serono's ability to develop new products, any failure to receive anticipated regulatory approvals, any problems in commercializing current products as a result of competition or other factors, our ability to obtain reimbursement coverage for our products, the outcome of government investigations and litigation and government regulations limiting our ability to sell our products. Serono has no responsibility to update the forward-looking statements contained in this press release to reflect events or circumstances occurring after the date of this press release.

Certain statements included in this press release, which are not historical facts, are forward-looking statements. Such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent our expectations or beliefs and involve certain risks and uncertainties, including those described in our public filings with the United States Securities and Exchange Commission; also including, but not limited to, changes in interest rates, competitive pressures, changes in customer mix, changes in third party reimbursement rates, financial stability of major customers, changes in government regulations or the interpretation of these regulations, changes in supplier relationships, growth opportunities, cost savings, revenue enhancements, synergies and other benefits anticipated from acquisition transactions, difficulties relative to integrating acquired businesses, the accounting and tax treatment of acquisitions, and asserted and unasserted claims, which could cause actual results to differ from those in the forward-looking statements. The forward-looking statements by their nature involve substantial risks and uncertainties, certain of which are beyond our control, and actual results may differ materially depending on a variety of important factors. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date herein.

For more information, please contact:
Serono, Inc., Rockland, MA
Media Relations:
Dana Jessup
Tel. +1 781 681 2443
Fax: +1 781 681 2935
http://www.seronousa.com/

Source: Serono, Inc.

CONTACT: Dana Jessup of Serono, Inc., +1-781-681-2443

Web site: http://www.fertilitylifelines.com/
http://www.seronousa.com/


 

©2000-2008 InternationalAdoptionStories.com

 
Sign Up for our
Adoption Newsletter!
 
Name:
Email: